“Dr. Rafal Farjo, Chief Operating Officer of eyecro, gives a seminar to Members-in-Training on Transitioning from Academia to a Start-up. At the 2013 Annual meeting of the Association for Research in vision and Ophthalmology in Seattle.”
“For patients with neovascular age-related macular degeneration (nAMD), a major cause of visual impairment worldwide,[1] the advent of anti–vascular endothelial growth factor (VEGF) intravitreal injections has been an undeniable breakthrough. Anti-VEGF therapy allows for greater control of the exudative process, which can dramatically improve outcomes compared with observation alone.” “Achieving and maintaining a dry macula in the…
EyeCRO is thrilled to announce the first clinical application of our groundbreaking MiDROPS® technology.
New findings from a landmark clinical trial show that although certain gene variants may predict whether a person is likely to develop age-related macular degeneration (AMD), these genes do not predict how patients will respond to Lucentis™ and Avastin™, the two medications most widely used to treat the “wet” form of AMD. This new data…
For decades, scientists have looked for explanations as to why certain conditions occur with age, among them memory loss, slower reaction time, insomnia and even depression. They have scrupulously investigated such suspects as high cholesterol, obesity, heart disease and an inactive lifestyle. Now a fascinating body of research supports a largely unrecognized culprit: the aging…
Daily aspirin use among seniors may double their risk of developing a particularly advanced form of age-related macular degeneration, a debilitating eye disease, a large new European study suggests. The possible link involves the so-called “wet” type of age-related macular degeneration (AMD), a significant cause of blindness in seniors. http://www.nlm.nih.gov/medlineplus/news/fullstory_120483.html
Inmed Pharmaceuticals Inc. (NASD: INM) has secured a worldwide license to formulate any cannabinoid molecule using MiDROPS® for ophthalmic instillation. Click here to read the full press release.